ERBB2 and breast carcinoma: In the four molecular subtypes of breast cancer, sGRP78 levels were all evidently increased, especially in HER2‐positive, Luminal B and triple‐negative (TNBC) types (Figure 1B), suggesting a potential role of sGRP78 as a serum biomarker to diagnose breast cancer.